Market Signal Briefing

486 Followers

Analyst’s Disclosure: I/we have a beneficial long position in the shares of PRL:CA either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

, /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of ordinary shares of uniQure N.V. (NASDAQ: QURE) between September 24, 2025, and October 31, 2025, inclusive (the "Class Period"), of the important April 13, 2026 lead plaintiff deadline.

So What: If you purchased uniQure ordinary shares during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the uniQure class action, go to https://rosenlegal.com/submit-form/?case_id=53025 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 13, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, defendants misrepresented and/or failed to disclose that: (1) the design of uniQure's Pivotal Study (a study of uniQure's leading drug candidate in patients with Huntington's Disease) — including comparison of the Pivotal Study results to the ENROLL-HD external historical data set— was not fully approved by the U.S. Food and Drug Administration (the "FDA"); (2) defendants downplayed the likelihood that, despite purportedly highly successful results from the Pivotal Study, uniQure would have to delay its Biologics License Application ("BLA") timeline to perform additional studies to supplement its BLA submission; and (3) as a result, defendants' statements about uniQure's business, operations, and prospects lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the uniQure class action, go to https://rosenlegal.com/submit-form/?case_id=53025 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

     Laurence Rosen, Esq.
     Phillip Kim, Esq.
     The Rosen Law Firm, P.A.
     275 Madison Avenue, 40th Floor
     New York, NY 10016
     Tel: (212) 686-1060
     Toll Free: (866) 767-3653
     Fax: (212) 202-3827
     [email protected]
     www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

The chip giant has invested tens of billions from its fast-growing war chest to become the industry's most powerful kingmaker.

Apple co-founder Steve Wozniak discusses AI and the reliance on technology on 'The Claman Countdown.'

Prospera Energy Inc. (TSXV: PEI) (OTC Pink: GXRFF) ("Prospera", "PEI", the "Company", or the "Corporation")
Calgary, Alberta--(Newsfile Corp. - March 23, 2026) -

Luseland Field Update
Prospera Energy is pleased to provide an operations update highlighting significant momentum across its Western Canadian heavy oil asset base. The Company's Luseland property in Saskatchewan has reached its highest production levels in almost a decade, a direct result of Prospera's systematic well reactivation program and the operational discipline implemented since the current management team assumed control in late 2024.

Figure 1 - Luseland Pool oil production demonstrating >300% increase in production in <18 months (with further growth underway).

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/12143/289657_prospera.jpg

Wells reactivated during 2025 continue to perform exceptionally well, with production rates still climbing, validating the Company's capital-efficient, reactivation-first development model and providing a reliable base upon which to layer additional growth.

Figure 2 - Luseland 10-08 well with continuously increasing oil production as a result of oil cuts rising.

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/12143/289657_8db3c105042e0bd9_004full.jpg

The 2026 reactivation program has already brought new wells online that are producing at strong initial rates. The Company attributes these results to several enhanced engineering and optimization strategies implemented this year, including the deployment of bigger downhole PCP pumps, undersized rotors for improved run-life and sand-management, additional recycle pumps installed on individual wells, increased recycle pump capacities across the field, and a more controlled ramp-up phase designed to maximize long-term well productivity and reliability. These operational refinements represent a meaningful step forward in the Company's approach to reactivation economics and are expected to improve both initial production rates and sustained well performance across future reactivations.

Additionally, the corporation has re-entered existing legacy Luseland wells in order to deploy enhanced production engineering and downhole strategies to add significant incremental barrels to the well, based on reservoir analysis and cleaning up perforations.

Figure 3 - Luseland 10-04 well after downhole sand cleanout, pump upgrade, and recycle pump. Numerous other opportunities being capitalized for similar incremental production increase.

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/12143/289657_8db3c105042e0bd9_005full.jpg

Following spring break-up, the Company expects to deploy a two-rig program focused on Luseland well upgrades and additional well reactivations, alongside targeted workovers at its Cuthbert property. This program is designed to maintain production growth momentum throughout 2026 with consistent month over month increases in operating and free cash flows as the program completes.

As additional wells are brought online at Luseland, the Company benefits from meaningful operating cost reductions on a per-barrel basis. Prospera's Luseland operations carry a significant fixed-cost component - including power, field staff, trucking infrastructure, and facility maintenance - that is absorbed more efficiently as incremental production is added. Each barrel of incremental production carries a disproportionately higher netback and margin, creating a compounding economic benefit as the field scales. In anticipation of potential supply chain tightness driven by the current higher commodity price environment, the Company has proactively pre-ordered critical parts and equipment to ensure its development program is not delayed by material shortages.

Shubham Garg, Chairman of the Board, commented: "The results we are seeing across Luseland are exactly what we set out to achieve with Prospera's business strategy of low-cost reactivations. Our 2025 reactivations are still climbing, our 2026 wells are coming on stronger than ever with our refined engineering strategies, and we have a clear runway ahead of us with the two-rig spring/summer program. The scaling economics at Luseland are powerful, every well we bring on makes the entire field more profitable. We have pre-ordered the parts we need to execute without interruption, and we intend to keep our foot on the gas."

Shares for Debt
Prospera has entered into settlement agreements with a total of 39 arm's length vendors, representing an aggregate of $1,611,394.43 in outstanding trade payables, to be satisfied through the issuance of 45,011,398 common shares. These counterparties are long-term strategic vendors that form part of the Company's ongoing, day-to-day procurement and field operations across its heavy oil asset base. Many of these vendors have supported Prospera through various phases of operational activity, and the successful negotiation of these settlements reflects continued commercial alignment and mutual confidence in the Company's forward strategy. Importantly, the willingness of these core vendors to accept equity consideration reinforces their commitment to maintaining and expanding their working relationship with Prospera as operations scale.

The settlements are structured as follows:

Three vendors have collectively settled $12,157.51 through the issuance of 243,150 common shares at a deemed price of $0.050 per share.One vendor has settled $2,438.58 through the issuance of 60,000 common shares at a deemed price of $0.041 per share.Three vendors have collectively settled $242,877.12 through the issuance of 6,071,928 common shares at a deemed price of $0.040 per share.One vendor has settled $30,000.00 through the issuance of 810,000 common shares at a deemed price of $0.037 per share.Thirty-one vendors have collectively settled $1,323,921.22 through the issuance of 37,826,320 common shares at a deemed price of $0.035 per share.The shares will be subject to a trading restriction of four months and a day from the date of issuance and are subject to TSXV acceptance. Overall, these settlements strengthen Prospera's balance sheet, preserve near-term liquidity, and further solidify relationships with essential long-term service providers integral to the Company's ongoing field development and procurement strategy.

Shares for Debt Update
Prospera announces an update to its previously announced shares-for-debt settlement originally disclosed on February 15, 2026. The Company has entered into debt settlement agreements with thirteen arm's length vendors to settle an aggregate of $79,532.98 in outstanding trade payables through the issuance of 1,590,660 common shares of the Company at a deemed price of $0.050 per common share. All shares issued pursuant to the settlement are subject to a statutory hold period of four months and one day from the date of issuance in accordance with applicable securities legislation. The transactions have been accepted by the TSX Venture Exchange.

About Prospera
Prospera Energy Inc. is a publicly traded Canadian energy company specializing in the exploration, development, and production of crude oil and natural gas. Headquartered in Calgary, Alberta, Prospera is dedicated to optimizing recovery from legacy fields using environmentally safe and efficient reservoir development methods and production practices. The company's core properties are strategically located in Saskatchewan and Alberta, including Cuthbert, Luseland, Hearts Hill, and Brooks. Prospera Energy Inc. is listed on the TSX Venture Exchange under the symbol PEI and the U.S. OTC Market under GXRFF.

Prospera reports gross production at the first point of sale, excluding gas used in operations and volumes from partners in arrears, even if cash proceeds are received. Gross production represents Prospera's working interest before royalties, while net production reflects its working interest after royalty deductions. These definitions align with ASC 51-324 to ensure consistency and transparency in reporting.

FORWARD-LOOKING STATEMENTS
This news release contains forward-looking statements relating to the future operations of the Corporation and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will," "may," "should," "anticipate," "expects" and similar expressions. All statements other than statements of historical fact included in this release, including, without limitation, statements regarding future plans and objectives of the Corporation, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements.

Although Prospera believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because Prospera can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, risks associated with the oil and gas industry in general (e.g., operational risks in development, exploration and production; delays or changes in plans with respect to exploration or development projects or capital expenditures; the uncertainty of reserve estimates; the uncertainty of estimates and projections relating to production, costs and expenses, and health, safety and environmental risks), commodity price and exchange rate fluctuations and uncertainties resulting from potential delays or changes in plans with respect to exploration or development projects or capital expenditures.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of Prospera. As a result, Prospera cannot guarantee that any forward-looking statement will materialize, and the reader is cautioned not to place undue reliance on any forward- looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release, and Prospera does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by Canadian securities law.

Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/289657

Source: Prospera Energy Inc.

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

, /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Soleno Therapeutics, Inc. (NASDAQ: SLNO) between March 26, 2025 through November 4, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.

So what: If you purchased Soleno common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Soleno class action, go to https://rosenlegal.com/submit-form/?case_id=43959 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 5, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) the Soleno Phase 3 clinical trial program for diazoxide choline extended-release tablets ("DCCR") had systematically downplayed, misrepresented, and/or concealed significant evidence of safety concerns potentially related to the administration of DCCR, including issues related to excess fluid retention in clinical trial participants; (2) as a result, the administration of DCCR to treat hyperphagia in individuals with Prader-Willi syndrome ("PWS") posed materially greater safety risks than disclosed by Soleno or its executives; and (3) as a result, DCCR had materially lower commercial viability and undisclosed risks related to the likelihood of significant and widespread adverse events after its commercial launch, including risks related to patient discontinuation rates, lower patient adoption, prescriber reluctance, adverse regulatory action, and potential reputational and legal fallout. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Soleno class action, go to https://rosenlegal.com/submit-form/?case_id=43959 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

     Laurence Rosen, Esq.
     Phillip Kim, Esq.
     The Rosen Law Firm, P.A.
     275 Madison Avenue, 40th Floor
     New York, NY 10016
     Tel: (212) 686-1060
     Toll Free: (866) 767-3653
     Fax: (212) 202-3827
     [email protected]
     www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

By Reuters

March 24, 20261:07 AM UTCUpdated 10 mins ago

A tank and an oil pump jack of the state oil company PDVSA facility is seen in Lagunillas, Venezuela October 14, 2022. REUTERS/Issac Urrutia/File Photo Purchase Licensing Rights, opens new tab

March 23 (Reuters) - Venezuela's oil ​exports brought ‌in $18.2 billion in ​revenues ​last year, the ⁠central ​bank said ​on Monday, down from ​the $18.4 ​billion brought in ‌the ⁠year before.

The monetary authority ​had ​not ⁠given updates ​on ​the ⁠figure since ⁠2018.

The Reuters Power Up newsletter provides everything you need to know about the global energy industry. Sign up here.

Reporting ​by ​Reuters; Editing by ​Tom Hogue

Our Standards: The Thomson Reuters Trust Principles., opens new tab

MONTRÉAL, March 23, 2026 (GLOBE NEWSWIRE) -- Boralex Inc. (the "Corporation") is aware of recent statements in the media regarding a strategic review of alternatives being conducted by the Corporation. The Corporation confirms that its Board of Directors has formed a special committee to review and recommend strategic alternatives. The special committee is continuing its strategic review and there can be no assurance that such review will result in a transaction. The Corporation remains focused on its stated business strategy and enhancing value for its shareholders. The Corporation does not intend to make any further comment unless or until there is a definitive transaction to announce or unless otherwise determined that further disclosure is appropriate or required by law.

Caution Regarding Forward-Looking Statements

Some of the statements contained in this press release are forward-looking statements within the meaning of securities legislation, including statements about the review of strategic alternatives available to the Corporation and the potential outcome thereof, which are based on current expectations. Boralex would like to point out that, by their very nature, forward-looking statements involve risks and uncertainties such that its results or the measure it adopts could differ materially from those indicated by or underlying these statements, or could have an impact on the degree of realisation of a particular forward-looking statement. The important risks and uncertainties that may cause the actual results and future events to differ significantly from the expectations currently expressed include the risk that the strategic review process may not result in a transaction on suitable terms, or at all, and other risks and uncertainties affecting the Corporation, including those considered in the sections dealing with risk factors and uncertainties appearing in the Corporation's MD&A for the fiscal year ended December 31, 2025. Unless otherwise specified by the Corporation, the forward-looking statements do not take into account the possible impact on its activities, transactions, non recurring items or other exceptional items announced or occurring after the statements are made. There can be no assurance as to the materialisation of the results, performance or achievements as expressed or implied by forward-looking statements. The reader is cautioned not to place undue reliance on such forward-looking statements. Unless required to do so under applicable securities legislation, Boralex management does not assume any obligation to update or revise forward-looking statements to reflect new information, future events or other changes.

About Boralex

At Boralex, we have been providing affordable renewable energy accessible to everyone for over 35 years. As a leader in the Canadian market and France's largest independent producer of onshore wind power, we also have facilities in the United States and in the United Kingdom. Over the past five years, our installed capacity has increased by more than 50%, reaching 3,783 MW as at December 31, 2025. We are developing a portfolio of projects in development and construction of 8.2 GW in wind, solar and BESS projects, guided by our values and our corporate social responsibility (CSR) approach. Recognized as Best Corporate Citizen in Canada by Corporate Knights, Boralex is actively participating in the fight against global warming. Thanks to our fearlessness, our discipline, our expertise and our diversity, we continue to be an industry leader. Boralex's shares are listed on the Toronto Stock Exchange under the ticker symbol BLX.

For more information, visit boralex.com or sedarplus.ca. Follow us on Facebook and LinkedIn.

For more information

MEDIAINVESTOR RELATIONSCamille Laventure
Senior Advisor, Public Affairs and External Communications
Boralex Inc.
438 883-8580
[email protected]éphane Milot
Vice President, Investor Relations & Financial Planning and Analysis
Boralex Inc.
+1 514 213 1045
[email protected]   Source: Boralex inc.

New York, New York--(Newsfile Corp. - March 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) between August 3, 2023 and December 26, 2025, inclusive (the "Class Period"), of the important April 6, 2026 lead plaintiff deadline.

SO WHAT: If you purchased Ultragenyx common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Ultragenyx class action, go to https://rosenlegal.com/submit-form/?case_id=52472 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 6, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants provided investors with material information concerning Ultragenyx's expected results for its Phase III Orbit and Cosmic Studies, which tested setrusumab (UX 143) in patients with Osteogenesis Imperfecta ("OI"). Defendants' statements included, among other things, confidence in setrusumab's ability to ultimately trigger a decrease in the OI patients' annualized fracture rate, alongside confidence in the study designs to demonstrate such ability and reduce testing variability that could interfere with such a result.

The lawsuit claims that defendants provided these overwhelmingly positive statements to investors while simultaneously disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of setrusumab's potential, as well as the true risk inherent in the study protocols put forth; notably, that while setrusumab does increase material bone density, this increase does not correlate to a decrease in annualized fracture rates or otherwise, that the Phase III Orbit and Cosmic studies were much less likely to be able to demonstrate such a link than management claimed. The lawsuit claims that such statements absent these material facts caused Ultragenyx shareholders to purchase Ultragenyx securities at artificially inflated prices. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Ultragenyx class action, go to https://rosenlegal.com/submit-form/?case_id=52472 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

-------------------------------

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/289661

Source: The Rosen Law Firm PA

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

The Schwab Intermediate-Term U.S. Treasury ETF faces heightened duration risk amid inflationary pressures from ongoing geopolitical conflict. SCHR's nearly 5-year duration makes it highly sensitive to shifts in US yield curve, with recent 0.4% YTM uptick causing a 2% price drawdown. Fed rate cuts are off the table while oil logistics remain disrupted, sustaining a 'higher for longer' rates environment and pressuring intermediate Treasuries.

Resolv managed to burn around 9 million USR held by the attacker, but roughly $0.5 million in redemptions had already been processed.

USR, an overcollateralized stablecoin natively backed by ETH and maintained by the Resolv protocol, lost its peg on March 22 after an attacker minted millions of unbacked tokens and reportedly extracted at least $25 million.

Here’s how the incident went down, according to blockchain analytics firm Chainalysis.

Attacker Exploits Minting Key to Create $80M in Unbacked USR In a thread posted on X earlier today, Chainalysis explained that the attacker gained access to Resolv’s AWS Key Management Service, where a privileged signing key was stored. The access allowed them to authorize minting operations using the protocol’s own permissions.

There were two standout transactions, the first minting 50 million USR, and the second adding another 30 million to bring the total to 80 million tokens. But according to Chainalysis, the minting operations were backed by rather small USDC deposits worth between $100,000 and $200,000, which the criminal used to trigger inflated swap outputs.

They then moved quickly, converting the newly minted USR into wrapped staked USR (wstUSR), which is a derivative that represents a share of a staking pool rather than a fixed token amount. After that, they swapped the funds into other stablecoins and then into ETH, obscuring their trail by rotating through several decentralized exchange pools and bridges.

Resolv Labs confirmed the breach, stating that the unauthorized minting had been enabled by a compromised private key. The team paused contracts shortly after detecting the issue and managed to burn nearly 9 million USR that the attacker had in their possession. They also reported that about $0.5 million in redemptions had been processed before operations were halted.

Per Chainalysis, the attacker controls about 11,400 ETH, worth about $25 million at the time the theft took place. They also hold about 20 million wstUSR, which were valued at much lower levels.

You may also like: ZachXBT Uncovers Coordinated Network Exploiting Political Fear to Fuel Cryptocurrency Scams FBI Warns of Fake Token Scam on Tron The Institutional Pivot: Why 74% of Large Investors Are Bullish on Crypto Right Now USR Depegs Immediately after the attack, USR plunged to a new all-time low near $0.14 per CoinGecko data. However, it has since recovered slightly, but the value at press time still represented a drop of over 57% in the last 24 hours.

According to the Resolv team, there are still at least 71 million illicitly minted tokens in USR’s circulating supply, which CoinGecko puts at just north of 176 million tokens. However, the team has initiated a redemption process for all USR minted before the incident, starting with allowlisted users.

The episode is especially damaging, considering a recent survey by Ripple found that 74% of finance executives see stablecoins as useful tools for managing cash flow and treasury operations. At the same time, 89% of them said they give great priority to secure custody when selecting service providers, which points to the importance of infrastructure safeguards.

Resolv has said that it is working with partners, law enforcement, and analytics firms to trace funds and recover assets, and it has warned users not to trade with the affected tokens during the recovery process.

Tags:

Dogecoin is trading near historic lows, but a technical setup demonstrates that the current price structure is setting up one of the most consequential trades in the memecoin’s history. 

The setup, which is based on a bi-weekly chart by crypto analyst Crypto Patel, points to a pattern that has been quietly forming since 2021, one that, if it resolves as history shows, could deliver returns measured not in percentages but that could create new crypto millionaires.

A Five-Year Pattern Reaching Its Breaking Point Technical analysis shows that since Dogecoin’s parabolic peak in May 2021, price action has carved out a descending triangle on the bi-weekly chart. This structure is defined by a falling upper trendline pressing down on price from above and a horizontal support base holding firm below. Every rally attempt since that peak has printed a lower high. Every dip has found the same floor.

Although Dogecoin broke above the upper trendline of the descending triangle in late 2024, the rally was eventually rejected just below $0.50. This rejection has been playing out with lower lows, and the Dogecoin price is now back to the horizontal support base of the triangle.

Source: Chart from Crypto Patel on X The latest price now puts Dogecoin compressing around $0.095, pinned inside what crypto analyst Crypto Patel identifies as the tightest price compression in Dogecoin’s history. Interestingly, this compression around $0.09 has lasted for almost two months. The longer a pattern like this builds, the more kinetic energy accumulates inside it. A resolution, when it comes, is likely to be violent.

The Targets For Crypto Millionaires: From $0.28 To $2 This is not the first time Dogecoin has gone through a prolonged accumulation phase. The bullish outlook is that the current correction can act as a base for a much larger rally that creates a new wave of crypto millionaires once there’s an upward bounce. Crypto Patel outlined a sequence of upside targets that Dogecoin investors can look forward to for reversals during the predicted expansion phase. 

The first level is around $0.28, which is based on a resistance zone encountered by a Dogecoin price rally in September 2025. Dogecoin is trading at $0.09 at the time of writing. If it is able to break above $0.28, that would place it at a return of over 200% from the current price. A break above $0.28 opens the door to target 2 around $0.50, which is around the December 2024 order block, and it could act as the next major resistance before continuation.

Target 3 is above the current 2021 all-time high of $0.7316 and at the psychologically important $1 price level. The most optimistic projection is a price target of $2, which would represent a gain of over 2,100% from the lower end of the current accumulation zone.

DOGE trading at $0.09 on the 1D chart | Source: DOGEUSDT on Tradingview.com Featured image from Getty Images, chart from Tradingview.com

SHIB climbed above $0.000006, buoyed by easing Middle East tensions, a 637% burn rate spike, and growing institutional interest in the meme coin sector.

Shiba Inu posted a 8.63% gain at the time of writing, pushing its price to $0.00000615. The token held firm above the $0.000006 support level and outpaced the broader crypto market, which advanced 2.57% to a total capitalization of $2.42 trillion. The move reflected a shift in investor appetite from risk aversion to high-beta assets.

The primary catalyst was a de-escalation in Middle East tensions. U.S. President Donald Trump reportedly deferred planned military action against Iran, opening a five-day window for diplomatic negotiations. Markets interpreted the move as a reduction in near-term conflict risk, triggering a global relief rally across risk assets.

Bitcoin rose nearly 4% during the same period, holding above $70,000, a level widely regarded as critical for sustaining bullish momentum across the wider crypto market. Meme coins, typically among the most volatile assets in the space, responded sharply to the improved sentiment.

Derivatives and On-Chain Data Signal Rising MomentumTrading volume in Shiba Inu derivatives rose 100.32%, reaching approximately $194.44 million. Open interest climbed 10.12% to $45.03 million, signaling that traders are actively establishing and maintaining leveraged positions. These figures point to heightened conviction in near-term price movement.

The MACD histogram has shifted into positive territory, suggesting that upward momentum is building. The Chaikin Money Flow indicator also registered a positive reading, confirming that capital inflows into SHIB are sustained rather than speculative in nature.

If buyers sustain control above $0.000006, the next resistance targets stand at $0.0000065 and $0.0000070. Spot trading volume climbed 67% to 169.65 billion SHIB over the period. Analysts note that a failure to defend the $0.000006 support could expose the token to a pullback toward $0.0000055. For now, buyers maintain the upper hand.

Burn Rate Spike and Regulatory Clarity Add Structural SupportThe Shiba Inu burn rate surged 637% within 24 hours, with over 8 million tokens permanently removed from circulation. Data from Shibburn confirmed the activity. This accelerated supply reduction reinforces the deflationary mechanism built into the token's design and strengthens its scarcity narrative among long-term holders.

On the regulatory front, U.S. authorities classified Shiba Inu as a digital commodity. As previously reported, the designation eases compliance uncertainty that has weighed on several altcoins and positions SHIB more clearly within the existing financial regulatory framework.

ENRICH your inbox with our best storiesDon’t miss out and join our newsletter to get the latest,
well-curated news from the crypto world!

Newton Gitonga covers cryptocurrencies, blockchain, and digital finance. He specializes in breaking down complex trends with clear, data-driven reporting. His work focuses on market analysis, technical insights, and the evolving role of altcoins in shaping global markets.

Read more about

Latest Shiba Inu News Today (SHIB)

TL;DR

BlackRock experiences a combined net outflow of over $77 million from its Bitcoin and Ethereum ETFs. iShares Bitcoin Trust (IBIT) saw 658 BTC withdrawn, while iShares Ethereum Trust (ETHA) lost 14,802 ETH. Despite these movements, both funds maintain substantial holdings, with IBIT holding 781,651 BTC and ETHA containing 3,167,035 ETH, indicating continued investor confidence in major cryptocurrencies.
BlackRock begins the week with notable crypto outflows as investors adjust their positions. On March 23, the asset manager reported a total net cash outflow exceeding $77 million from its two flagship spot cryptocurrency ETFs, reflecting active portfolio rebalancing.

BlackRock Crypto Outflows Highlight Investor Movements The iShares Bitcoin Trust (IBIT) led the withdrawals with 658 BTC, valued at approximately $46 million. Lookonchain data indicates this was the largest single-day cash outflow among spot Bitcoin ETFs. However, IBIT remains heavily invested, with net holdings reaching 781,651 BTC, worth more than $54.7 billion. Over the past week, the fund saw inflows of 2,471 BTC, suggesting that longer-term investors continue to support Bitcoin accumulation.

Meanwhile, BlackRock’s iShares Ethereum Trust ETF (ETHA) recorded a net outflow of 14,802 ETH, equal to around $31.74 million. This brings total Ethereum sales over the past seven days to 35,041 ETH, roughly $75.12 million. The fund still holds 3,167,035 ETH, with a notional value of $6.79 billion, underscoring that substantial institutional support remains for Ethereum.

Market Rebound Offsets Outflow Effects Interestingly, the ETF outflows coincided with an upward move in cryptocurrency prices. Bitcoin climbed 2.36% in the past 24 hours to trade near $70,410, while Ethereum gained 2.67%, reaching approximately $2,136. Analysts note that macroeconomic announcements, including talks of a potential US-Iran agreement, contributed to this bullish sentiment. The market rally shows that short-term outflows from ETFs do not necessarily reflect weakening demand for digital assets.

Outlook Suggests Ongoing Institutional Engagement Despite the net withdrawals, the sustained high holdings in both Bitcoin and Ethereum ETFs indicate confidence among institutional investors. Market observers see these outflows as part of routine liquidity adjustments rather than a trend of exit from crypto exposure. As global interest in Bitcoin and Ethereum continues to grow, large-scale investors appear prepared to maintain significant positions, supporting stability and gradual growth in the sector.

The blurring of the lines between the traditional financial sector and the blockchain financial sector continues. In March, credit card giant Mastercard (MA +0.82%) unveiled a massive new blockchain payment initiative that will feature 85 different crypto industry partners.

One of those partners is Ripple, the fintech company behind the XRP (XRP +3.17%) crypto token. That's good news for XRP investors everywhere. In a best-case scenario, this partnership could become the next catalyst to send the price of XRP soaring.

Mastercard's crypto initiative The new Crypto Partner Program from Mastercard is the latest sign that blockchain technology is gaining a real foothold in the traditional financial services sector. The new strategic initiative is based on one core idea: connecting blockchain technology with Mastercard's existing global payments infrastructure to make payments faster, cheaper, and more efficient.

Image source: Getty Images.

To make that possible, Mastercard will run a series of blockchain payment pilots with top fintech companies, including both Ripple and PayPal. At some point, if the pilots prove successful, more of Mastercard's transaction volume will run on blockchain rails. That includes cross-border payments, business-to-business payments, and global payouts.

The long-term outlook for XRP This new strategic initiative dovetails nicely with Ripple's five-year strategy for XRP, which is focused on institutional adoption. Ripple is trying to find as many partners as possible, as quickly as possible, to use the XRP blockchain. Currently, over 300 banks and financial institutions use the XRP blockchain for cross-border payments and liquidity management.

Signing up Mastercard as a partner certainly highlights that things are headed in the right direction. Ripple made its name by offering faster and cheaper cross-border transactions to big financial institutions and banks. Now it's offering the same efficiencies and cost savings to Mastercard.

Today's Change

(

3.17

%) $

0.04

Current Price

$

1.43

Deals like these are why future price predictions for XRP can sometimes be sky-high. It's not hard to find XRP price predictions of $100 or more. There just seems to be so much potential out there. All XRP has to do is find a huge market opportunity and then establish a foothold using its superior blockchain technology.

Just more hype and buzz? Keep in mind, however, that XRP has consistently overpromised and underdelivered in the past. Despite all the buzz and hype, XRP has never traded higher than $4 in more than a decade. So, while there's a lot going in XRP's favor right now, investors shouldn't immediately assume that XRP is headed to the moon anytime soon.

However, the new partnership with Mastercard is certainly a good sign of institutional adoption and better things to come soon. If you're looking for a budget-priced altcoin capable of soaring higher in 2026, XRP could be worth a closer look.

Dominic Basulto has positions in XRP. The Motley Fool has positions in and recommends Mastercard, PayPal, and XRP. The Motley Fool recommends the following options: long January 2027 $42.50 calls on PayPal and short March 2026 $65 calls on PayPal. The Motley Fool has a disclosure policy.

Ethereum is flashing early warning signs as momentum begins to shift beneath the surface. The RSI trendline break on the USDT pair suggests weakening strength, while the ETH/BTC pair now sits on the edge of following suit. With a familiar breakdown pattern taking shape, the risk of a double confirmation is rising, one that could open the door to a sharper move lower.

RSI Breakdown Signals Early Weakness On Ethereum/USDT According to a recent Ethereum analysis from Umair Crypto, the USDT pair has already seen its RSI trendline break, signaling an initial shift in momentum. The ETH/BTC pair is expected to follow suit shortly, making a new lower low a matter of when, not if.

This pattern mirrors a sequence recently observed with Solana. In that instance, the USDT pair’s RSI trendline fractured first while the BTC pair initially appeared to maintain its strength. Ethereum is now replicating this exact behavior, setting the stage for a similar recursive breakdown.

Source: Chart from Umair Crypto on X While the ETH/BTC pair is currently holding its levels, the analysis suggests this resilience is temporary. However, once the BTC pair loses its footing, the lack of support across both denominations will likely trigger a sharp move to the downside. This alignment represents the most volatile and high-risk version of a market breakdown for Ethereum.

Resilience Under Pressure, But At What Cost? The analyst went on to emphasize that both Bitcoin and Ethereum have shown notable strength throughout the intensity of the broader macro battle. That resilience is undeniable, but it hasn’t come without a cost. Rather than forming a solid base, the market has effectively been running on borrowed time, and the fatigue now visible on the charts suggests that the cost of that strength is beginning to surface. From this point, a move toward a lower low should not come as a surprise.

A major catalyst is adding to the current tension. Over $2.1 billion in BTC and ETH options is set to expire today, alongside Wall Street’s massive $5.7 trillion Triple Witching event. While such large expiries don’t directly trigger market direction, they tend to magnify existing momentum. In this case, the underlying structure already points to the downside, meaning any move could be accelerated under these conditions.

The breakdown sequence is also becoming increasingly clear. The USDT pair was the first to show weakness, losing its key structure and signaling the initial shift in momentum. 

Now, attention turns to confirmation from the ETH/BTC pair. When this alignment occurs, it typically leads to a more decisive and aggressive move lower as bearish pressure takes full control.

ETH trading at $2,169 on the 1D chart | Source: ETHUSDT on Tradingview.com Featured image from Pexels, chart from Tradingview.com

The Solana Foundation is making a bold move to attract large institutions by reframing privacy not as a limitation, but as a flexible, enterprise-grade feature. In a newly released report titled "Privacy on Solana: A Full-Spectrum Approach for the Modern Enterprise," the organization argues that the next wave of crypto adoption hinges on giving businesses granular control over data visibility.

This represents a notable departure from blockchain's traditional open-ledger philosophy. Public networks have long operated on pseudonymity — transactions are traceable, even if wallet addresses obscure real identities. While foundational, this model leaves gaps for enterprise needs. Banks may need to verify transactions without exposing counterparties. Payroll systems cannot afford to broadcast employee compensation data on a public chain.

The foundation's core technical argument centers on Solana's speed. Its high throughput and low latency, the report claims, make sophisticated privacy tools viable at near-web speeds — enabling real-world applications like encrypted order books and confidential credit risk calculations.

Rather than a one-size-fits-all solution, Solana presents privacy as a four-tier spectrum: pseudonymity, confidentiality, anonymity, and fully private systems. Each tier serves a distinct purpose. Pseudonymity masks identities while keeping transaction data open. Confidentiality encrypts sensitive figures like balances while keeping participants identifiable. Anonymity does the reverse. Fully private systems shield both identity and transaction data using zero-knowledge proofs and multiparty computation.

The report also tackles the regulatory tension head-on. Features like "auditor keys" allow authorized parties to decrypt transactions when legally required, while compliance wallets can verify regulatory status without revealing user identity — a critical safeguard amid growing anti-money laundering scrutiny.

The broader vision is composability: enterprises mixing and matching privacy tools based on specific operational needs, all within a single, unified blockchain ecosystem. For institutions navigating both data sensitivity and regulatory demands, Solana is positioning itself as the infrastructure layer that can handle both.

<Copyright ⓒ TokenPost, unauthorized reproduction and redistribution prohibited>

$17.0 Million YTD in New Contract Awards March 23, 2026 19:05 ET  | Source: CEMATRIX Corporation

CALGARY, Alberta, March 23, 2026 (GLOBE NEWSWIRE) -- CEMATRIX Corporation (TSX: CEMX) (OTCQB: CTXXF) ("CEMATRIX" or the "Company"), a specialty construction contractor that produces cellular concrete solutions on site and is a leading manufacturer and supplier of cellular concrete in North America, announces that it has won $4.7 million in new contract awards.

New Contract Award Details:

The awards are in the form of contracts and contracts in process. All of the work related to these awards is expected to be completed in 2026. Some of the larger awards include:

a grouting application for a city infrastructure project;a load reducing fill application for an abandonment project;the remaining awards are small to mid-sized projects for lightweight fill applications in Canada and the US. “Our sales momentum has continued into March. These awards continue to demonstrate the trust that our customers have in CEMATRIX’s sales and operations teams to consistently deliver quality solutions for their geotechnical construction needs. We continue to see strong bidding activity and a robust sales pipeline well into the future. We are now even closer to spring weather to kick start what we expect to be a busy 2026,” stated Mr. Randy Boomhour, President and CEO of CEMATRIX Corporation. “We remain passionate about providing value to our customers, by consistently delivering quality, cost-effective cellular concrete solutions, on time and on budget. Every successful project strengthens our reputation and makes the next sale easier.”

General Guidance:

“As we have shared many times with investors, we do not control when large scopes of work start and stop. These large scopes of work have significant impact to our financial results especially from quarter to quarter. These quarterly variations in revenue can cause concern among certain segments of our shareholders but our focus is always on the whole year. We do expect that our first quarter this year may be a little lower when compared to last year. That said, we also expect that this slower start to the year will be more than offset by an expected record second quarter to keep us on track in terms of financial performance for a really good year in 2026,” concluded Mr. Boomhour.

For more information about CEMATRIX please visit www.cematrix.com.

ABOUT CEMATRIX

CEMATRIX is a specialty construction contractor that produces cellular concrete solutions on site. Cellular concrete is a flowable, self-leveling, cement-based material with insulating properties. CEMATRIX provides customers with cost effective, innovative solutions to their geotechnical construction challenges.

Applications for cellular concrete include lightweight engineered fill, MSE & retaining wall fill, lightweight insulating road subbase, flowable self compacting fill, pipe & culvert abandonments, tunnel & annular grout, tunnel & shaft backfills, underwater / tremie fills, and shallow utility & foundation insulation.

CEMATRIX is a growth Company with significant revenue, positive EBITDA, positive cashflow from operations, a very healthy balance sheet, and a strong team in place. The Company’s wholly owned operating subsidiaries include CEMATRIX (Canada) Inc. (“CCI”), Chicago based MixOnSite USA Inc. (“MOS”), and Bellingham based Pacific International Grout Company (“PIGCO”). For more information, please visit our website at www.cematrix.com.

CAUTIONARY STATEMENT REGARDING FORWARD LOOKING STATEMENTS

The information in this press release includes certain forward-looking statements which may constitute forward-looking information under applicable securities laws. These forward-looking statements are based on currently available competitive, financial and economic data and operating plans but are subject to risks and uncertainties. Forward-looking statements may include, without limitation, statements regarding the operations, business, financial condition, expected financial results, performance, prospects, ongoing objectives, strategies and outlook for CEMATRIX, including statements regarding: the anticipated commencement and completion of the projects. Forward-looking statements may in some cases be identified by words such as "may," "will," "expects," "target," "future," "plans," "believes," "anticipates," "estimates," "projects," "intends," "should" or the negative of these terms, or similar expressions.

In addition to events beyond CEMATRIX's control, there are factors which could cause actual or future results, performance or achievements to differ materially from those expressed or inferred herein including, but not limited to, the risk of not being able to meet contractual schedules and other performance requirements, the risks associated with a third party’s failure to perform; the risk of not being able to meet its labour needs at reasonable costs; the risk of not being able to address any supply chain issues which may arise. These forward-looking statements are based on a variety of factors and assumptions including, but not limited to that: none of the risks identified above materialize, there are no unforeseen changes to economic and market conditions and no significant events occur outside the ordinary course of business. These assumptions are based on information currently available to CEMATRIX, including information obtained from third-party sources. While CEMATRIX believes that such third-party sources are reliable sources of information, CEMATRIX has not independently verified the information. CEMATRIX has not ascertained the validity or accuracy of the underlying economic assumptions contained in such information from third-party sources and hereby disclaims any responsibility or liability whatsoever in respect of any information obtained from third-party sources.

Risk factors are discussed in greater detail in CEMATRIX’s 2025 Management’s Discussion and Analysis for the fiscal year ended December 31, 2025 and CEMATRIX’s Annual Information Form dated December 31, 2025, each filed on SEDAR+ (www.sedarplus.ca). Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and CEMATRIX undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

The Toronto Stock Exchange does not accept responsibility for the adequacy or accuracy of this release.

For further information, please contact:

CEMATRIX Investor Relations
Attention: Randy Boomhour, CEO
Phone: 403-219-0484
Email: [email protected]

or

Bristol Capital
Attention: Glen Akselrod, President
Phone: (905) 326-1888 ext. 1
Email: [email protected]

, /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Gartner, Inc. (NYSE: IT) between February 4, 2025 and February 2, 2026, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 18, 2026.

So What: If you purchased Gartner common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do Next: To join the Gartner class action, go to https://rosenlegal.com/submit-form/?case_id=56538 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 18, 2026. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the Case: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose facts concerning the true state of Gartner's growth rates; notably, that it was not truly equipped to handle ongoing challenges in its industry to either meet consulting revenue targets or to increase or even maintain its contract value ("CV") growth rate; Gartner's repeated claims of being able to achieve 12-16% CV growth rates in a "normal" macroeconomic environment proved to be unrealistic. When the true details entered the market, the lawsuit claims that investors suffered damages. 

To join the Gartner class action, go to https://rosenlegal.com/submit-form/?case_id=56538 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

     Laurence Rosen, Esq.
     Phillip Kim, Esq.
     The Rosen Law Firm, P.A.
     275 Madison Avenue, 40th Floor
     New York, NY 10016
     Tel: (212) 686-1060
     Toll Free: (866) 767-3653
     Fax: (212) 202-3827
     [email protected]
     www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Grocery Outlet To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Grocery Outlet between August 5, 2025 and March 4, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - March 23, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Grocery Outlet Holding Corp. ("Grocery Outlet" or the "Company") (NASDAQ: GO) and reminds investors of the May 15, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) the Company had "expanded too quickly" into new stores; (2) the Company's purportedly strong financial and operational growth was being artificially supported by excessive rapid store expansion; (3) as a result, the Company was unable to achieve the sustainable growth required to meet its previously set guidance; (4) the Company's Restructuring Plan would require further Optimization to achieve its operational goals, including significant store closures and asset write-downs; and (5) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On March 4, 2026, after the market closed, Grocery Outlet announced results for the fourth quarter and full fiscal year 2025, revealing the Company's full year financial results which missed guidance on nearly every major financial metric. The Company reported full year 2025 adjusted EBITDA of $254.3 million (missing prior guidance of $258 at the low end); net sales of $4.69 billion, (missing prior guidance of $4.70 billion at the low end); comparable store sales which increased by 0.5% on a 52-week basis (missing prior guidance of 0.6% to 0.9%), and diluted adjusted earnings per share of $0.76 (missing prior guidance of $0.78 at the low end). Moreover, the Company revealed it was adding an additional "optimization plan" on top of its "restructuring plan," and "reshaping [its] new store growth strategy" including the "closure of 36 financially underperforming stores." Further, the Company also "determined that the long-lived assets of the Closure Stores were impaired, and recognized $110 million of non-cash charges in Impairment of long-lived assets on the condensed consolidated statements of operations and comprehensive income (loss)." Finally, the Company stated that it estimates "between $14 million and $25 million in net total restructuring charges in fiscal 2026, including between $51 million and $63 million of estimated cash expenditures primarily for lease termination fees, and between $11 million and $14 million of bad debt expense, partially offset by net non-cash write-off of right-of-use assets and lease liabilities associated with these leases of between $(48) million and $(52) million."

On the same date, the Company held an earnings call in conjunction with releasing fourth quarter 2025 results. During the earnings call, the Company's CEO, Defendant Potter, further revealed that the Company had "made the difficult decision to close 36 locations" in part because "it's clear now that we expanded too quickly, and these closures are a direct correction."

On this news, Grocery Outlet's stock price fell $2.45, or 27.9%, to close at $6.34 per share on March 5, 2026, on unusually heavy trading volume.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Grocery Outlet's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Grocery Outlet class action, go to www.faruqilaw.com/GO or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/289577

Source: Faruqi & Faruqi LLP

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Picard Medical To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Picard Medical between September 2, 2025 and October 31, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - March 23, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Picard Medical, Inc. ("Picard Medical" or the "Company") (NYSE American: PMI) and reminds investors of the April 13, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) that Picard was the subject of a fraudulent stock promotion scheme involving social media-based misinformation and impersonated financial professionals; (2) that insiders and/or affiliates used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign; and (3) that Picard's public statements and risk disclosures omitted any mention of the false rumors and artificial trading activity driving the stock price.

On October 24, 2025, Picard Medical, Inc. (NYSE: PMI) shares closed at $5.31, a steep decline from the prior trading session's close of $13.20 on October 23, 2025. This represents a drop of $7.89 per share, or approximately a 59.8% decrease in value in a single session, marking one of the most significant one-day declines since the company's recent IPO.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Picard Medical's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Picard Medical class action, go to www.faruqilaw.com/PMI or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/289588

Source: Faruqi & Faruqi LLP

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

NRx Pharmaceuticals, Inc. (NRXP - Free Report) came out with quarterly earnings of $0.19 per share, beating the Zacks Consensus Estimate of a loss of $0.09 per share. This compares to a loss of $0.3 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +323.53%. A quarter ago, it was expected that this company would post a loss of $0.11 per share when it actually produced a loss of $0.18, delivering a surprise of -63.64%.

Over the last four quarters, the company has surpassed consensus EPS estimates just once.

NRx Pharmaceuticals, which belongs to the Zacks Medical - Drugs industry, posted revenues of $0.98 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 84.4%. This compares to zero revenues a year ago.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

NRx Pharmaceuticals shares have lost about 31.7% since the beginning of the year versus the S&P 500's decline of 5%.

What's Next for NRx Pharmaceuticals?While NRx Pharmaceuticals has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for NRx Pharmaceuticals was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.01 on $14.25 million in revenues for the coming quarter and $0.13 on $83.6 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Drugs is currently in the top 36% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Vivos Therapeutics, Inc. (VVOS - Free Report) , another stock in the same industry, has yet to report results for the quarter ended December 2025.

This company is expected to post quarterly loss of $0.53 per share in its upcoming report, which represents a year-over-year change of -89.3%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Vivos Therapeutics, Inc.'s revenues are expected to be $7.2 million, up 94.6% from the year-ago quarter.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Paysafe To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Paysafe between March 4, 2025 and November 12, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - March 23, 2026) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Paysafe Limited ("Paysafe" or the "Company") (NYSE: PSFE) and reminds investors of the April 7, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Paysafe's ecommerce business had significant exposure to a single high risk client; (2) as a result, the Company's credit loss reserves and/or write-offs were understated; (3) Paysafe had an undisclosed issue with higher risk Merchant Category Codes, making its client services difficult to bank; (4) the foregoing issues were likely to have a material negative impact on the Company's revenue growth and overall revenue mix; (5) as a result, Paysafe was unlikely to meet its own previously issued financial guidance for fiscal year 2025; and (6) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On November 13, 2025, before the market opened, Paysafe announced third quarter financial results, including revenue of $433.8 million, which missed consensus estimates by $5.8 million, and a net loss of $87.7 million, a steep drop from the prior year period wherein the Company's net loss was only $12.98 million. The Company also slashed full year 2025 expected revenue to $17 million at the midpoint, and adjusted EPS $0.50 at the midpoint.

The Company further revealed that its credit loss expense for the quarter was $13,220 "primarily [as] the result of a specific provision for expected chargebacks related to an individual merchant in the Merchant Solutions segment." The report revealed write-offs of $9,924 "driven by the write off of irrecoverable amounts receivable in the Merchant Solutions segment."

On the same date, the Company held an earnings call during which CEO Bruce Lowthers revealed the Company "had a last-minute client that had to shut down that caused several million-dollar write-down in Q3." Lowthers further revealed the Company is in a market tier with "higher risk MCC [Merchant Category Codes] codes." Lowthers explained "those things sometimes are a little difficult to bank" and "sometimes the banks aren't open to the additional risk" "so, we've had a little bit of challenge with that with some of those MCC codes."

On this news, Paysafe's stock price fell $2.80, or 27.6%, to close at $7.36 per share on November 13, 2025, on unusually heavy trading volume.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Paysafe's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Paysafe Limited class action, go to www.faruqilaw.com/PSFE or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/289587

Source: Faruqi & Faruqi LLP

Ready to Announce with Confidence? Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.

Contact Us

Nucor (NUE - Free Report) ended the recent trading session at $160.62, demonstrating a +1.29% change from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily gain of 1.15%. On the other hand, the Dow registered a gain of 1.38%, and the technology-centric Nasdaq increased by 1.38%.

Coming into today, shares of the steel company had lost 11.91% in the past month. In that same time, the Basic Materials sector lost 16.03%, while the S&P 500 lost 5.69%.

Analysts and investors alike will be keeping a close eye on the performance of Nucor in its upcoming earnings disclosure. The company's earnings report is set to go public on April 27, 2026. In that report, analysts expect Nucor to post earnings of $2.84 per share. This would mark year-over-year growth of 268.83%. In the meantime, our current consensus estimate forecasts the revenue to be $8.69 billion, indicating a 11.04% growth compared to the corresponding quarter of the prior year.

For the annual period, the Zacks Consensus Estimates anticipate earnings of $11.84 per share and a revenue of $35.15 billion, signifying shifts of +53.57% and +8.17%, respectively, from the last year.

Investors should also pay attention to any latest changes in analyst estimates for Nucor. These revisions typically reflect the latest short-term business trends, which can change frequently. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.

Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.

The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.9% higher. Currently, Nucor is carrying a Zacks Rank of #3 (Hold).

Digging into valuation, Nucor currently has a Forward P/E ratio of 13.39. This indicates a premium in contrast to its industry's Forward P/E of 12.28.

We can additionally observe that NUE currently boasts a PEG ratio of 0.57. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. By the end of yesterday's trading, the Steel - Producers industry had an average PEG ratio of 0.45.

The Steel - Producers industry is part of the Basic Materials sector. This industry, currently bearing a Zacks Industry Rank of 215, finds itself in the bottom 13% echelons of all 250+ industries.

The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.

Crescent Energy (CRGY - Free Report) closed at $12.50 in the latest trading session, marking a -1.34% move from the prior day. The stock's performance was behind the S&P 500's daily gain of 1.15%. Meanwhile, the Dow gained 1.38%, and the Nasdaq, a tech-heavy index, added 1.38%.

Shares of the oil and gas company have appreciated by 18.3% over the course of the past month, outperforming the Oils-Energy sector's gain of 8.53%, and the S&P 500's loss of 5.69%.

The investment community will be closely monitoring the performance of Crescent Energy in its forthcoming earnings report. It is anticipated that the company will report an EPS of $0.45, marking a 19.64% fall compared to the same quarter of the previous year. In the meantime, our current consensus estimate forecasts the revenue to be $1.17 billion, indicating a 22.9% growth compared to the corresponding quarter of the prior year.

In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $1.48 per share and a revenue of $4.44 billion, indicating changes of -17.78% and +23.91%, respectively, from the former year.

Any recent changes to analyst estimates for Crescent Energy should also be noted by investors. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability.

Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.

The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. At present, Crescent Energy boasts a Zacks Rank of #3 (Hold).

In the context of valuation, Crescent Energy is at present trading with a Forward P/E ratio of 8.58. This valuation marks a discount compared to its industry average Forward P/E of 18.79.

The Alternative Energy - Other industry is part of the Oils-Energy sector. At present, this industry carries a Zacks Industry Rank of 88, placing it within the top 36% of over 250 industries.

The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

To follow CRGY in the coming trading sessions, be sure to utilize Zacks.com.